1. Агранат В.З. Радиоизотопная диагностика злокачественных опухолей. «Медицина», М., 1967, 228 с.
2. Акимочкина З.Е. — Опыт применения радиоактивного фосфора (Р32) для диагностики поверхностно расположенных опухолей и опухолевидных образований. Автореф. дисс. … к.м.н. М., 1961.
3. Афанасьева Н.Н., Ерёмин В.К., Строкан Н.Б., Тархин Д.В. — Полупроводниковые детекторы для внутриполостной и внутритканевой радиофосфорной диагностики рака. — «Медицинская радиология», 1983, N9, 62-64.
4. Баженова А.П., Мадич К.К., Хаханашвили Г.Н., Сихарулидзе А.В. Опыт применения операции Пэйти-Дисона при раке молочной железы. Хирургия, 1987, N 4, 37-42.
5. Бассалык Л.С. (ред.) Рецепторы стероидных гормонов в опухолях человека. М., 1987, с.223.
6. Богатырев В.Н., Ермилова В.Д., Петрова А.С. Лазерная проточная цитофлуорометрия как дополнительный метод определения степени дифференцировки опухоли у больных раком молочной железы. — Архив патологии, 1986, т.XLVIII, N1, стр. 44 — 48.
7. Богатырев В.Н. Анеуплоидные и диплоидные новообразования молочных желез и их связь с прогнозом заболевания. — Лабораторное дело, 1989, N 11, стр. 54 — 56.
8. Богатырев В.Н. Значение количественных методов исследования (морфометрии, проточной цитофлуорометрии, сканирующей микрофотометрии) в клинической онкоцитологии. Диссертация на соискание ученой степени доктора медицинских наук, Москва, 1991, 426 с.
9. Богатырев В.Н., Портной С.М., Лактионов К.П., Летягин В.П. Проточная цитометрия при раке молочной железы T1-2N0M0: анализ 10-летних наблюдений. 1 съезд онкологов стран СНГ 3 — 6 декабря 1996. Москва. Материалы съезда. Часть 2, 482 -483.
10. Вишнякова В.В. О возможности уменьшения объёма оперативного вмешательства в радикальном лечении рака молочной железы. Вестник АМН СССР, 1976, 2, 57-61.
11. Гродзенский Д., Ильина Л. — Исследование фосфорного обмена при физиологических и патологических условиях с помощью радиоактивного фосфора. — Физиологический журнал СССР имени И.М.Сеченова, 1940, 29, 4, 341-344.
12. Двойрин В.В. Статистика рака молочной железы в России. Вестник ОНЦ РАМН, 1994, 1, 3-12.
13. Двойрин В.В., Аксель Е.М., Трапезников Н.Н. Статистика злокачественных новообразований в России и некоторых других странах СНГ в 1994 году. М., 1995.
14. Ерёмин В.К., Летягин В.П., Полевая Е.Б., Портной С.М., Строкан Н.Б., Тархин Д.В. Способ оценки эффективности консервативного лечения солидных злокачественных опухолей. Патент РФ N 1776137.
15. Ерёмин В.К., Портной С.М., Строкан Н.Б., Тархин Д.В. Способ оценки операбельности рака молочной железы III стадии. Патент РФ N 1776138.
16. Ерёмин В.К., Портной С.М., Строкан Н.Б., Тархин Д.В. Способ прогнозирования течения рака молочной железы III стадии. Патент РФ N 1807773.
17. Ермилова В.Д., Портной С.М., Репетюк Д.В., Коротких И.Ю., Балакирева Г.В., Ахметов М.Ш., Лактионов К.П., Летягин В.П. Значение некоторых морфологических признаков для результатов лечения больных раком молочной железы T1-2N0M0. 1 съезд онкологов стран СНГ 3 — 6 декабря 1996, Москва. Материалы съезда. Часть 2, 490 — 491.
18. Зауташвили З.О. Мультицентрический рак молочной железы. Автореферат дисс. … к.м.н. М., 1989, 24 с.
19. Зубовский Г.А., Габуния Р.И. — Основы радионуклидной диагностики. В: Клиническая рентгенорадиология., Москва, Медицина, 1985, т.4, 6 — 59.
20. Кампова — Полевая Е.Б. Рак молочной железы у женщин молодого возраста. Автореф. дисс. … к. м.н., Москва, 1975, 26 с.
21. Керимов Р.А. Клиническая оценка факторов прогноза при III стадии рака молочной железы. Автореферат дисс. … к.м.н. М., 1989, 24 с.
22. Коптяева И.В. Доклинический рак молочной железы T1N0M0. Дисс. на соискание уч. ст. к.м.н., М.,1996, 113 с.
23. Корман Д.Б., Батомункова Т.В., Крутова Т.В., Демидов В.П., Франк Г.А., Островцев Л.Д., Сарибекян Э.К. Пролиферативная активность клеток рака молочной железы. — Известия АН СССР, Сер. биол., 1988, N5, 701-708.
24. Крылова М.О. Редкие формы рака молочной железы (Клинико-морфологические особенности и факторы прогноза). — Автореф. дисс. …к.м.н., Москва, 1989.
25. Кушлинский Н.Е., Портной С.М., Репетюк Д.В., Кузьмина З.В., Герштейн Е.С., Балакирева Г.В., Ахметов М.Ш., Лактионов К.П., Летягин В.П. Влияние уровня рецепторов эстрогенов (РЭ), рецепторов прогестерона (РП) на результаты лечения больных раком молочной железы T1-2N0M0. 1 съезд онкологов стран СНГ 3 — 6 декабря 1996, Москва. Материалы съезда. Часть 2, 499-500.
26. Лактионов К.П., Портной С.М., Барканов А.И., Коптяева И.В., Коротких И.Ю., Блохин С.Н., Репетюк Д.В., Ахметов М.Ш. Органосохраняющие операции при раке молочной железы I — II стадии. 1 съезд онкологов стран СНГ 3 — 6 декабря 1996. Москва. Материалы съезда. Часть 2, 500.
27. Летягин В.П., Лактионов К.П., Ермилова В.Д., Крылова М.О., Высоцкая И.В., Котов В.А. Редкие формы рака молочной железы. М., 1995, 146 с.
28. Маклецова Н.П. Применение радиоактивного фосфора (Р32) с диагностической и терапевтической целью. Автореф. дисс. … к.м.н. Л., 1961.
29. Меленчук И.П. Применение Р32 для диагностики заболеваний молочной железы. Мед. радиология, 1964, 8, 81-87.
30. Моисеенко В.М., Семиглазов В.Ф., Климашевский В.Ф., Семячкина С.О., Черномордикова М.Ф., Пожарисский К.М. Потенциальная и фактическая скорость роста рака молочной железы. — Вопросы онкологии, 1991, 37,2, 174-179.
31. Моисеенко В.М. Кинетические особенности роста рака молочной железы и их значение для обоснования раннего выявления и лечения. Автореферат дисс. … д.м.н., Санкт-Петербург, 1994, 48 с.
32. Непесов А.К.,»Клиническая оценка распространённости рака молочной железы.», Автореферат дисс. … к.м.н., М.,1985.
33. Николаева Т.Г., Добрынин Я.В., Басов Б.Н., Чиквашвили Б.Ш., Воротников И.К., Летягин В.П. Проточная ДНК-цитометрия в прогнозировании течения рака молочной железы. Вестник ОНЦ АМН России, 1994, 1, 30 — 31.
34. Поддубный Б.К., Габуния Р.И., Унгиадзе Г.В., Нургужаев К.С. Результаты комплексной бронхофиброскопической и радиометрической диагностики рака лёгкого. — Мед.радиология, 1982, 27, 7, 89-90.
35. Поддубный Б.К., Кувшинов Ю.П., Шишков А.С., Мазуров С.Т., Любарский В.И.- Фиброгастроскопия, лапароскопия и эндоскопическая радиометрия в уточнённой диагностике эндофитной формы рака желудка. — Зравоохранение, Кишинёв, 1983, N2, 45-46.
36. Поддубный Б.К., Кныш В.И., Веселов В.В., Ожиганов Е.Л., Шабаров В.Л. — Сочетанная колоноскопическая и радиометрическая диагностика рецидивов рака толстой кишки. — Клиническая медицина, 1984, 62, N7, 90-92.
37. Портной С. М. Возможности диагностики, прогнозирования течения и коррекции лечения рака молочной железы с помощью внутритканевого радиофосфорного исследования. М.1992, 54 с.
38. Портной С.М., Р.И.Габуния, В.П.Годин, В.П.Летягин. Практическое использование определения относительного накопления 32Р в опухоли при раке молочной железы. Вопросы онкологии,1992, 38, 8, 986 — 992.
39. Портной C.М., Р.И.Габуния, В.П.Годин, В.П.Летягин. Внутритканевая радиофосфорная диагностика опухолей молочной железы. Медицинская радиология, 1992, N7-8, 16 — 18.
40. Портной C.М., Р.И.Габуния, В.П.Годин, В.П.Летягин, З.В.Кузьмина. Влияние метастатического поражения регионарных лимфатических узлов, гистологической формы рака, уровня рецепторов эстрогенов и прогестерона на относительное накопление 32Р в опухоли при раке молочной железы. Вестник ОНЦ АМН России, 1993, Приложение, 42 — 44.
41. Портной C.М., А.И.Барканов, И.В.Коптяева, К.П.Лактионов, И.Б.Морошкин, Н.В.Чхиквадзе. Органосохраняющее лечение рака молочной железы: проблемы первых лет. Тезисы Всесоюзного симпозиума «Скрининг в раннем выявлении опухолей репродуктивной системы и проведение органосохраняющего лечения». Ленинград, 1991, 78 — 79.
42. Портной C.М., К.П.Лактионов, Р.И.Габуния, В.П.Годин, В.П.Летягин, С.В.Ширяев. Относительное накопление 32Р опухолью как фактор прогноза у больных раком молочной железы. 1 съезд онкологов стран СНГ 3 — 6 декабря 1996. Москва. Материалы съезда. Часть 2, 511.
43. Портной C.М., Лактионов К.П., Барканов А.И., Коптяева И.В. Косметический эффект органосохраняющих операций при раке молочной железы: больные удовлетворены чаще, чем врачи. The First international symposium plastic and reconstructive surgery in oncology. Moscow, Russia. March 19 — 21 1997. 132.
44. Самгина А.А., Летягин В.П., Кузьмина З.В. Роль рецепторного статуса опухоли в выборе адъювантной терапии больных раком молочной железы в репродуктивном возрасте. Вопросы онкологии, 1992, 38, 7, 780-787.
45. Семиглазов В.Ф. Пути повышения эффективности лечения рака молочной железы. — В: Тезисы Всесоюзного симпозиума “Сравнительная оценка выживаемости больных раком молочной железы при различных методах лечения.” 8 — 9 декабря 1983. с.3 — 5.
46. Семиглазов В.Ф., Иванов В.Г., Иванова О.А., Моисеенко В.М., Цырлина Е.В., Божок А.А. Эффективность адъювантной гормонотерапии при раке молочной железы. Вопросы онкологии, 1996, 42, 1, 56-61.
47. Смирнова К.Д., Муравьева Н.И., Вишнякова В.В. Рецепторы эстрадиола в ткани опухоли молочной железы женщин, находящихся в менопаузе. — Вестник АМН СССР, 1978, 2, 47-50.
48. Соколова И.Г. Предоперационная полихимиотерапия в комплексном лечении местно распространённого рака молочной железы», Дисс. на соиск. уч. степ. к.м.н., М., 1983, 143 с.
49. Уманский Ю.А. — О накоплении искусственно-радиоактивного фосфора в опухолях. — Автореферат дисс. … к.м.н., Киев, 1951.
50. Холдин С.А. Злокачественные опухоли молочной железы. В: Злокачественные опухоли. Л.,1962, т.3,ч.1, 31-167.
51. Хотченкова Н.В. Оптимизация и стандартизация условий метода определения рецепторов стероидных гормонов в опухолях человека. Автореферат диссертации на соискание учёной степени кандидата медицинских наук. М.1990.
52. Шевченко И.Т., Значковский Н.Г., Городыский В.И., Весёлая И.В. — О применении радиоактивного фосфора для диагностики рака молочной железы. — Вестник рентгенологии и радиологии, 1954, 4, 49-53.
53. Aaltomaa S., Lipponen P., Eskelinen M., Kosma V.M., Marin S., Alhava E., Syrjanen K. Hormone receptors as prognostic factors in female breast cancer. Ann Med, 1991,23, 6, 643-648.
54. Aaltomaa S., Lipponen P., Eskelinen M., et al. Comparison of classic and quantitative prognostic factors in hormone receptor-positive and hormone receptor-negative female breast cancer. Am J Surg, 1993, 165, 3, 307-311.
55. Abraham D.C., Jones R.C., Jones S.E., et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer, 1996, 78, 1, 91-100
56. Albaum H., Goldfeder A., Eisler L. — Incorporation and Turnover of Radiophosphorus in Mouse Mammary Tumors (dbrB and C3H).- Cancer Res., 1952, 12, 3, 188-191.
57. Arriagada R., Rutqvist L.E., Mattsson A., Kramar A., Rotstein S. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol 1995, 13, 12, 2869-2878.
58. Arriagada R., Le M.G., Rochard F., Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. J Clin Oncol, 1996,14, 5, 1558-1564.
59. Auchincloss H. Significance of location and number of axillary metastases in carcinoma of the breast. Ann. Surg., 1963, 158, 37-46.
60. Auer G., Caspersson T., Wallgren A. DNA content and survival in mammary carcinoma. — Anal. Quant. Cytol. Hist., 1980, 3, 161 — 165.
61. Auer G., Ericksson E., Azavedo E., Caspersson T., Wallgren A. Prognostic significance of nuclear DNA content in mammary carcinomas in humans. — Cancer Res., 1984, v. 44, 394 — 396.
62. Baak J.P., Von Dop H., Kuaver P.H., et al. — The value of morphometry to classic prognosticators in breast cancer. — Cancer, 1985, 56, 374 — 382.
63. Baak J.P.A., Kurver P.H.J., Van Diest P.J., Galen E.M., Van Wisse-Brekelmans E.C.M., Matze-Kok P., Littooy J.Q. Data-processing and analysis in the multicenter morphometric mammarycarcinoma project. — Path.Res.Pract., 1989, 185, 657 — 663.
64. Badwe R.A., Gregory W.M., Chaudary M.A., et al. Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet, 1991, 337 (8752), 1261-1264.
65. Baildam A.D., Zaloudik J., Howell A. et al. DNA analysis by flow cytometry: responce to endocrine treatment and prognosis in advanced carcinoma of the breast. — Br.J.Cancer, 1987, 55, 533- 559.
66. Balslev I., Christensen I.J., Rasmussen B.B., et al. Flow cytometric DNA ploidy defines patients with poor prognosis in node-negative breast cancer. Int J Cancer, 1994, 56, 1, 16-25.
67. Barbareschi M., Dalla Palma P., Bevilacqua P., et al. Invasive node-negative breast carcinoma: multivariate analysis of the prognostic value of peritumoral vessel invasion compared with that of conventional clinico-pathologic features. Anticancer Res, 1994, 14, 5B, 2229-2235.
68. Barlogie B., Goehde W., Johnston D.A., et al. Determination of ploidy and proliferative characteristics of human solid tumors by puls cytophotometry. — Cancer Res., 1978, 38, 3333 — 3339.
69. Barlogie B., Drewinko B., Schumann J. et al. Cellular DNA content as a marker of neoplasia in a man. — Amer. J. Med., 1980, 69, 195-203.
70. Barnum C.R., Huseby R.A., Vermund H. — A time study of the incorporation of radiophosphorus into the nucleic acids and other compounds of a transplanted mouse mammary carcinoma. — Cancer research, 1953, 13, 12, 880-889.
71. Baum M., Ebbs S.R., Houghton J., A`Hern R.P., Riley D. The Cancer Research Campaign trials of adjuvant therapy for early breast cancer. Acta Oncologica, 1989, 28,6,907-912.
72. Baum M. Current role of adjuvant hormone therapy in the management of early carcinoma of the breast. Anticancer Drugs 1995,6,Suppl 2,40.
73. Bezwoda W.R., Esser J.D., Dansey R., et al. The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen. Cancer, 1991, 68, 4, 867-872.
74. Bloom H.J.G., Richardson W.W. Histological grading and prognosis in breast cancer. British J Cancer, 1957, 11, 359-377.
75. Bonadonna G., Valagussa P, Dose-response effect of adjuvant chemotherapy in breast cancer. N. Engl. J.Med., 1981, 304, 10-15.
76. Bonadonna G., Valagussa P, Rossi A., et al. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res.Treat. 1985, 5, 95-115.
77. Cascinelli N, Greco M, Bufalino R, et al.: Prognosis of breast cancer with axillary node metastases after surgical treatment only. Eur J Cancer Clin Oncology, 1987, 23, 6, 795-799.
78. Chaiken L., Rege S., Hoh C., et al. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiat Oncol Biol Phys, 1993, 27, 2, 455-464.
79. Clark G.M., Dressler L.G., Owens M.A., et al. — Prediction of relapse of survival in patients with node-negative breast cancer by DNA flow cytometry. — N. Engl. J. Med., 1989, 320, 627-633.
80. Consensus Conference Adjuvant chemotherapy for breast cancer, JAMA, 1985,254, 3461-3463.
81. Contesso G., Mouriesse H., Friedman S., et al. The importance of histological grade in long-term prognosis of breast cancer: A study of 1010 patient, uniformly treated at the Institute Gustave-Roussy. J.Clin. Oncol., 1987, 5, 1378-1386.
82. McCready D.R., Chapman J.W., Hanna W.M., Mobbs B.G. The importance of considering adjuvant therapy in prognostic investigations of breast cancer. Proc Annu Meet Am Soc Clin Oncol, 1993,12, A222.
83. Dale P.S., Giuliano A.E.Nipple-areolar preservation during breast-conserving therapy for subareolar breast carcinomas. Arch Surg 1996, 131, 4, 430-433.
84. van Dalen A., vd Linde D.L., Heering K., et al. How could therapy response be measured in breast cancer patients? Anticancer Res, 1992, 12, 6A, 1904.
85. Dao T.H., Rahmouni A., Servois V., Nguyen-Tan T. MR imaging of the breast in the follow-up evaluation of conservative nonoperatively treated breast cancer. Magn Reson Imaging Clin N Am, 1994, 2, 4, 605-622.
86. Darzynkiewicz Z., Traganos F., Sharpless T., Melamed M.R. Conformation of RNA in situ as studied by acridine orange staining and automated cytofluorometry. — Exp. Cell. Res., 1975, 95, 1, 143-153.
87. Diel I.J., Kaufmann M., Solomayer E.F., et al. Micrometastatic tumor cells in bone marrow versus nodal status in breast cancer: impact on prognosis in 727 patients with primary breast cancer. In: Adjuvant Therapy of Primary Breast Cancer. 5-th Internationational Conference. March 1 — 4 , 1995. St.Gallen. Switzerland. P14.
88. McDivitt R.W., Boyce W., Gersell D. Tubular carcinoma of the breast. Am J Surgical Pathology 1982, 6, 401-411.
89. Dressler L.G., Seamer L., Owens M.A. et al. DNA flow cytometry and prognostic factors in 1331 frosen breast cancer specimens. — Cancer, 1988, v.61, 420 — 427.
90. Early Breast Cancer Trialists` Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet, 1992,339, 1-15, 71-85.
91. Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med 1995, 333, 22,1444-1455.
92. Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: an overview of the randomized trials. Lancet, 1996, 348, 1189-1196.
93. Ellis F., Hoch-Ligeti C., Oliver R. — Investigation of the effect of x-radiation on the localization of radioactive phosphorus in breast tumors. British J. Cancer, 1951, 5, 1, 45-53.
94. Elston C.W. Grading of invasive carcinoma of the breast. In: Page D.L., Anderson T.J. (eds). Diagnostic Histopathology of the Breast. Churchill Livingstone, London, 1987, 300-311.
95. Ermilova V.D., S.M. Portnoj, D.V. Repetiuk, I.Yu. Korotkih, G.V.Balakireva, M.Sh. Akhmetov, K.P. Laktionov, V.P. Letyagin. Significance of Some Morphological Signs for Treatment Results in Breast Cancer T1-2N0M0 Patients. European J Cancer, 1996, v.32a, Suppl.2, 40, ref. PP-6 -13.
96. Eskelinen M., Lipponen P., Papinaho S., Aaltomaa S., KosmaV.M., Klemi P., Syrjanen K. DNA flow cytometry, nuclear morphometry, mitotic indices and steroid receptors as independent prognostic factors in female breast cancer. Int J Cancer, 1992, 51, 4, 555-561.
97. Espinal E.G., Ubios A.M., Cabrini R.L. — Salivary gland tumors inducede by 32P. — J. Oral Pathol., 1984, 13, 6, 686 — 691.
98. Ewers S.B., Langstroem E., Baldetorp B. et al. Flow cytometric DNA analysis in primary breast carcinomas and clinicopathologic correlations. — Cytometry, 1984, 5, 408-419.
99. Ewers S.B., Baldetorp B., Killander D. et al. Flow cytometry DNA ploidy and number of cell populations in the primary breast cancer and their correlation to the prognosis. Acta Oncol., 1989, 28, 6, 913 — 918.
100. Ewers S.B., Attewell R., Baldetorp B., et al. Flow cytometry DNA analysis and prediction of loco-regional recurrences after mastectomy in breast cancer. Acta Oncol 1992, 31, 7, 733-740.
101. Ferno M., Baldetorp B., Bendahl P.O., et al. Recurrence-free survival in breast cancer improved by adjuvant tamoxifen — especially for progesterone receptor positive tumors with a high proliferation. Breast Cancer Res Treat 1995, 36, 1,23-34.
102. Fisher B. et al., Ten year follow-up results of patients with carcinoma of the brest in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg. Gynecol. Obstet., 1975, 140, 528-534.
103. Fisher B., N. Wolmark. Limited surgical management for breast cancer: a commentary on the NSABBP reports. World J Surg. 1985, 9, 5, 682-691.
104. Fisher B, Fisher ER, Redmond C, et al.: Tumor nuclear grade, estrogen receptor, and progesterone receptor: their value alone or in combination as indicators of outcome following adjuvant therapy for breast cancer. Breast Cancer Research and Treatment 1986,7, 3, 147-160.
105. Fisher B., Fisher E.R., Redmond C.K. Ten year results from the NSABP clinical trial evaluating the use of L-phenylalanine mustard (L-Pam) in the management of primary breast cancer. J.Clin.Oncol.,1986, 4, 929-941.
106. Fisher B., Anderson S., Redmond C.K., Wolmark N., Wickerham D.L., Cronin W.M. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995, 333, 22, 1456-1461.
107. Fisher E.R., Palikar A.S., Redmond C., et al., Pathologic findings from the National Surgical AdJuvant Project (protocol no.4) VI. Invasive papillary carcinoma. Am J Clinical Pathology, 1980, 73, 313-322.
108. Fisher ER, Redmond C, Fisher B, et al.: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP): prognostic discriminants for 8-year survival for node-negative invasive breast cancer patients. Cancer, 1990, 65, 9, Suppl, 2121-2128.
109. Focan C., Beauduin M., Salamon E., et al. High-dose medroxyprogesterone acetate (HDMPA) as adjuvant hormonotherapy for early breast cancer. Importance of age, menopausal and nodal status as prognostic determinants. Ten years results of a multicenter randomized trial. Anticancer Res 1995, 15, 5A, 1716-1717.
110. Fowble B.L., Schultz D.J., Overmoyer B., et al. The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys, 1994, 30, 1, 23-33.
111. Galimberti V., Zurrida S., Zanini V. Central small size breast cancer: how to overcome the problem of nipple and areola involvment. Eur J Cancer, 1993, 29A, 8, 1093-1096.
112. Gawne-Cain M.L., Smith E., Darby M., Given-Wilson R. The use of ultrasound for monitoring breast tumour response to pro- adjuvant therapy. Clin Radiol 1995, 50, 10, 681-686.
113. Gershon-Cohen J., Berger S.M., Kliсkstein H.S. -Roentgenography of breast cancer moderating concept of «biological predeterminism». Cancer — 1963, 16, 8, p.961-964.
114. Giard S., Vanderstichele S., Coche B., Laurent J.C. [Conservative surgical treatment of retro-areolar breast tumors. Local control and esthetic results]. J Gynecol Obstet Biol Reprod (Paris) 1996, 25, 3, 238-241.
115. Gilchrist K.W., Gray R., van Driel-Kulker A.M., et al. High DNA content and prognosis in lymph node positive breast cancer. A case control study by the University of Leiden and ECOG (Eastern Cooperative Oncology Group). Breast Cancer Res Treat 1993, 28, 1, 1-8.
116. Gnant MF, Seifert M, Jakesz R, et al.: Breast cancer and timing of surgery during menstrual cycle: a 5-year analysis of 385 pre-menopausal women. Int J Cancer, 1992, 52, 5, 707-712.
117. Goehde W. , Schumann J., Buchner Th. et al. Pulse cytophotometry — its application in tumor cell biology and clinical oncology. In: Flow cytometry and Sorting ( Eds.: Melamed M.R., Mullaney P.F., Mendelsohn M.L.). — New-York: John Willey & Sons Inc., 1979, 599 — 620.
118. Guenther J.M., Kirgan D.M., Giuliano A.E. Feasibility of breast-conserving therapy for younger women with breast cancer. Arch Surg 1996, 131, 6, 632-636.
119. McGuire W.L. Current status of estrogen receptors in human breast cancer.- Cancer, 1975, 36, Suppl. 2,638-644.
120. McGuire W.L. Steroid receptors in human breast cancer. — Cancer Res., 1978, 38, 11, part 2, 4289-4291.
121. Mc Guire W.L., Tandona K., Allred C., et al. How to use prognostic factors in axillary node-negative breast cancer patients. J.N.C.I., 1990, 82,1006-1015.
122. McGuire WL, Hilsenbeck S, Clark GM: Optimal mastectomy timing. Journal of the National Cancer Institute, 1992, 84, 5, 346-348.
123. Das Gupta N.N., Bhattacharya K.L., D.Choudhuri, et al. — The uptake of radioactive phosphorus in normal breast and breast tumors. — Acta radiol. (Stockh.), 1956, 45, 69-76.
124. Haagensen С, Stout A.P. Carcinoma of the breast. I — Results of treatment. Ann. Surg., 1942, 116, 801 — 815.
125. Haagensen С, Stout A.P. Carcinoma of the breast. II — Criteria of operability. Ann. Surg., 1943, 118, 859-870 & 1032-1051.
126. Haagensen C.D. A technique for radical mastectomy. Surgery, 1946, 19,1, 100-131.
127. Haagensen C. Diseases of the breast. 1965.
128. Halsted W.S. The results of operations for the cure of cancer of breast performed at Johns Hopkins Hospital from June 1889 to January 1894. John Hopkins Hosp. Rep., 1894, 4, 297-350.
129. Hauser H., Beham A., Steindorfer P., et al. [Breast cancer in the Catchment area of the Graz institute of pathology. Evaluation of morphologic parameters based on 1510 cases.] Wien Klin Wochenschr 1992, 104, 23, 717-720.
130. Hawkins R.A., Roberts M.M., Forrest A.P.M. Oestrogen receptors and breast cancer: current status. — British J. Surgery, 1980, 67, 153-169.
131. Haybittle J.L., Blamey R.W., Elston C.W. , et al. A prognostic index in primary breast cancer. British J. Cancer, 1982, 45, 361-366.
132. Hilf R., Feldstein M.L., Savlov E.D., et al., The lack of relationship between estrogen receptor status and response to chemotherapy. Cancer, 1980, 46, 2797-2800.
133. Holland P.A., Shah A., Howell A., Baildam A.D., Bundred N.J. Lobular carcinoma of the breast can be managed by breast-conserving therapy. Br J Surg 1995, 82, 10, 1364-1366.
134. Holt S., Croton R., Leinster S.J., et al.- In vitro thymidin labelling index in primary operable breast cancer. Eur. J. Surg. Oncol., 1986, 12, 1, 53-57.
135. Horwitz K.B., McGuire W.L., Pearson O.H., Segaloff A. Predicting response to endocrine therapy in human breast cancer: a hypothesis. — Science, 1975, 189, 4204, 726-727.
136. Horwitz K.B. How do breast cancers become hormone resistant? J Steroid Biochem Mol Biol, 1994, 49, 4-6, 295-302.
137. Hryniuk W. & Levine M.N. Analysis of dose intensity in chemotherapy trials in stage II breast cancer. J Clin Oncol, 1986, 4, 1162-1170.
138. Jager W., Sauerbrei W. Effect of timing of surgery during the menstrual cycle of premenopausal breast cancer patients. Breast Cancer Res Treat 1995, 34, 3, 279-287.
139. Jensen V., M.L. Jensen, H. Kiaer, J. Andersen, F. Melsen. Immunohistochemical Analyses of Proliferative Activity in Breast Carcinomas with Medullary Features. European J Cancer, 1996, 32a, Suppl.2, 55, ref. PP-9 — 1.
140. Joensuu H., Toikkanen S. Identification of subgroups with favorable prognosis in breast cancer. Acta Oncol, 1992, 31, 3, 293-301.
141. Jonat W., Maass H., Stolzenbach G., Trams G. Estrogen receptor status and response to polychemotherapy in advanced breast cancer. Cancer, 1980, 46, 2809-2813.
142. Jones H.B., Chaikoff I.L., Lawrence J.H. — Phosphorus metabolism of neoplastic tissues (mammary carcinoma, lymphoma, lymphosarcoma) as indicated by radioactive phosphorus. — Amer. J. of Cancer, 1940, 40, 2, 243-250.
143. Kallioniemi O.-P., Heitanen T., Mattila J. et al. Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. — Eur.J.Cancer Clin.Oncol., 1987, 23, 227 — 282.
144. Kallioniemi O.-P., Blanco G., Alavaikko M et al. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-Phase fraction. — A proposal classification of DNA histograms in breast cancer. Cancer, 1988, 62, 11, 2183 — 2190.
145. Kaplan E.L., Meier P. Nonparametric estimations from incomplete observations. J.Am. Statis. Assoc., 1958, 53, 457-481.
146. Kaplan E. Historical Development of 32P in bone therapy. In: Therapy in Nuclear medicine. N.Y., 1978, 237-249.
147. Kaufmann M. Review of known prognostic variables. Adjuvant therapy of primary breast cancer. 5th International Conference. March 1-4, 1995 St.Gallen, P25.
148. Klijn J.G.M.,, Look M., Meijer-van Gelder M., Seynaeve C., Bontenbal M., van Geel A.N., S.C. Henzen-Logmans S.C., van Putten W.L.J., Foekens_J.A. Incidence and Prognostic Value of Routine Clinical Parameters in 2273 Patients with Primary Breast Cancer Treated between 1978 -1990. European J Cancer, 1996, 32a, Suppl.2, 38, ref. PP-6-2.
149. Knight W.A., Livingston R.B., Gregory E.J., McGuire W.L. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer.- Cancer Res., 1977, 37, 12, 4669-4671.
150. Knopp M.V., Brix G., Junkermann H.J., Sinn H.P. MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Magn Reson Imaging Clin N Am 1994, 2, 4, 633-658.
151. Kohlhardt S.R., Blamey R.W., Pinder S.E., Ellis I.O., Elston C.W. Automated grading in a prognostic index. 7-th EORTC Breast Cancer Conference, Bordeaux, September 10-13 1996. 1996, PP 6 7.
152. Kollias J., C.W. Elston, I.O. Ellis, J.F.R. Robertson, R.W. Blamey. The Prognostic Importance of Tumour Grade in Lymph Node Positive Breast Cancer. 7-th EORTC Breast Cancer Conference, Bordeaux, September 10-13 1996. PP-6 6.
153. Kroman N.T., Hjgaard A.D., Andersen K.W., et al. [Menstrual cycle and surgery of breast cancer. Point of time for the surgery of primary breast cancer in connection with menstrual cycle is without prognostic significance]. Ugeskr Laeger 1995, 157, 43, 5989-5993.
154. Kuroishi T., Tominaga S., Morimoto T., et al. — Tumor Growth Rate and Prognosis of Breast Cancer Mainly Detected by Mass Screening. — Jpn. J. Cancer Res., 1990, 81, 5, 454-462.
155. Kurtz J.M., Spitalier J.-M., Amalric R. et al. Mammary recurrences in women younger than forty. Int.J. Radiation Oncology, Biology,Physics., 1988,15, 2, 271-276.
156. Kushlinsky N.E., Portnoj S.M., D.V.Repetiuk, Z.V.Kuzmina, E.S.Gershtein, G.V.Balakireva, M.Sh.Akhmetov, K.P.Laktionov, V.P.Letyagin. The levels of estrogen receptors (ER) and progesterone receptors (PR) and treatment results in breast cancer (BC) T1-2N0M0 patients. 7-th EORTC breast cancer working conference. European J Cancer 1996, 32a, Suppl.2, p.40.
157. Laerum O.D. , Farsund T. Clinical application of flow cytometry: a review. — Cytometry, 1981, 2, 1 — 13.
158. Law T.M., Hesketh P.J., Porter K.A. et al. Breast cancer in elderly women: presentation, survival, and treatment options. Surg Clin North Am 1996, 76, 2, 289-308.
159. Lemon HM; Rodriguez-Sierra JF. Timing of breast cancer surgery during the luteal menstrual phase may improve prognosis. Nebraska Med J., 1996,81, 4, 110-115.
160. Lethaby A.E., Mason B.H., Holdaway I.M., Kay R.G. Age and ethnicity as prognostic factors influencing overall survival in breast cancer patients in the Auckland region. Auckland breast cancer study group. N Z Med J, 1992, 105 (947), 485-488.
161. Levine M; Myles J; Shepherd L; El Kum N. Optimal timing of breast cancer surgery within the menstrual cycle: results from a prospective trial. Proc Annu Meet Am Soc Clin Oncol 1996, 15, A61.
162. Levitt S.H., Aeppli D.M., Nierengarten M.E. The importance of local control in the conservative treatment of breast cancer. Acta Oncol 1995, 34, 6, 839-844.
163. Lippman M.E., Allegra J.C.,Thompson E.B., et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N.Engl.J.Med., 1978, 298, 1223-1228.
164. Lluch A., Cervantes A., Marugan M.,et al. Neoadjuvant chemotherapy (NCT) of stage II-III breast cancer (BC). Determination of tumor size mammography (MA), ultrasonography (US) and clinical examination (CE) and comparison with pathological size (PS). Evaluation of response and correlation with clinical and biological parameters. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 1994, 13, A208.
165. Low-Beer B.V.A., Bell H.G., McCorcle H.J. et al., — Measurement of Radioactive Phosphorus in Breast Tumors in situ: a Possible Diagnostic Procedure. Preliminary Report. — Radiology, 1946, 47, 492-493.
166. Low-Beer V.A., Green R.B.- Radiophosphorus studies in breast tumors. Six years` investigation of the validity of the surface measurement method.- Cardiologia, 1952, 21, 4/5, 497-505.
167. Ludwig Breast Cancer Study Group. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet, 1984, 311, 1256-1260.
168. Lyman G.H., Lyman S.L., Balducci L. ,et al. Age and the risk of breast cancer recurrence. Proc Annu Meet Am Soc Clin Oncol, 1994, 13, A101.
169. Madden J.L. Modified radical mastectomy. Surg. Gynecol. Obstet., 1965, 121, 1221-1230.
170. Madden J.L., Kandalaft S., Borque R. Modified radical mastectomy. Ann. Surg., 1972, 175, 624-627.
171. Maddox W.A., Carpenter J.T., Laws H.L., et al. Does radical mastectomy still have a place in the treatment of breast cancer? Arch. Surg., 1987, 122, 1317-1320.
172. Mansini J.L., Berger U., Easton D., et al. Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br.Med.J.,1987, 295, 1093-1096.
173. Martin P.M., Romain S., Spyratos F., et al. [Reevaluation of indications for adjuvant hormone therapy in primary breast cancer with high metastatic risk.] Bull Cancer (Paris), 1991, 78,8, 709 — 723.
174. de Mascarel I., M. Durand, L. Mauriac, F. Bonichon, G. Mac Grogan, I. Soubeyran, V. Picot, J.M. Coindre, M. Trojani. Prognostic Significance of Obvious Peritumoral Emboli in 2692 Primary Operable Breast Carcinoma. 7-th EORTC Breast Cancer Conference, Bordeaux, September 10-13 1996. PP-6 4.
175. Melamed M.R., Mullaney P.F., Mendelsohn M.R. Flow cytometry and sorting. — New-York, 1979, 716p.
176. Meyer J.S., Friedman E., McCrate M.M., Bauer W. — Prediction of early course of breast carcinoma by thymidine labeling. — Cancer, 1983, 51, 10, 1879 — 1886.
177. Meyer J.S., Province M. Proliferative index of breast carcinoma by thymidine labelling: prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res. Treat., 1988, 12, 191-204.
178. Molnar L., Besznyak I., Koves I. Cancer of the breast in young women. Acta Chir Hung 1995, 35, 1-2, 5-11.
179. Muss H., Thor A., Kute T., et al. Erbb-2 (c-erbb-27; her -2/neu) and S-phase fraction (SPF) predict response to adjuvant chemotherapy in patients (PTS) with node positive (N+) breast cancer (BC): Cancer and Acute Leukemia Group B (CALGB) trial 8869. Proc Annu Meet Am Soc Clin Oncol, 1993, 12, A88.
180. Muss H., Wesley M., Chen V., Coates R., Austin D., Harlan L., Hunter C., Blacklow R., Shapiro S., Edwards B. Estrogen receptor (ER) and progesterone receptor (PR) are related to survival in black and white women with breast cancer (BC): the National Cancer Institute (NCI) black/white cancer survival study experience. Proc Annu Meet Am Soc Clin Oncol.,1994, 13, A117.
181. Nab H.W., Kluck H.M., Rutgers E.J., et al. Long-term prognosis of breast cancer: an analysis of 462 patients in a general hospital in South East Netherlands. Eur J Surg Oncol, 1995, 21, 1, 42-46.
182. Namer M., Abbes M., Ramaioli A., et al. Influence of age on the characteristics and the outcome of 2023 breast cancer patients. Proc Annu Meet Am Soc Clin Oncol, 1993,12, A29.
183. Namer M., Fumoleau P., Gerard J.P., et al. Node-positive Postmenopausal breast cancer patients: five-year follow-up results of a randomized trial testing the role of hormonal therapy (HT), chemotherapy (CT) or combination. Adjuvant therapy of primary breast cancer. 5-th International Conference. March 1-4, 1995 St.Gallen, P81.
184. Nathan B, Bates T, Anbazhagan R, et al.: Timing of surgery for breast cancer in relation to the menstrual cycle and survival of premenopausal women. British Journal of Surgery, 1993, 80, 1, 43.
185. Neff P.T., Bear H.D., Pierce C.V. et al. Long-term results of breast conservation therapy for breast cancer. Ann Surg 1996,223, 6, 709-716.
186. Negenbank W. Studies of human tumors by MRS: a Reiew. NMR in Biomedicene, 1992, 5, 303-324.
187. Nevinny H.B., Nevinny D., Roscoff C.B., et al., Prophylactic oophorectomy in breast cancer therapy. Am. J.Surgery, 1969,117, 531-536.
188. Nissen-Meier R., et al. Surgical adjuvant chemotherapy. Results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer, 1978, 41, 2088-2098.
189. Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Analysis at eight years by “Nolvadex” Adjuvant Trial Organisation. Br.J.Cancer., 1988, 57, 608-611.
190. Norden T., Lindgren A., Bergstrom R., Holmberg L. Defining a high mortality risk group among women with primary breast cancer. Br J Cancer, 1994, 69,3, 520-524.
191. Nordenskjold B., Stal O., Skoog L., et al. S-phase fraction and c-erbb-2 expression related to the survival benefit from adjuvant chemotherapy of breast cancer. Proc Annu Meet Am Soc Clin Oncol, 1994, 13, A70.
192. Onsrud M., Bosnes V., Grahu J., Engenest A. — Changes in lymphoid cell distribution after intraperitoneal administration of 32P colloids. — Acta Radiol. Ser. Oncol., 1985, 24,4, 331-335.
193. Osborne M.P., Borgen P.I. Role of mastectomy in breast cancer. Surgical Clinics of North America, 1990, 70, 5, 1023-1046.
194. Osborne M.P., Asina S., Wong G.Y., et al. Immunofluorescent monoclonal antibody detection of breast cancer in bone marrow: Sensitivity in a model system. Cancer Res., 1989, 49, 2510-2513.
195. Page D.L., Dixon J.M., Anderson T.J., et al. Invasive cribriform carcinoma of the breast. Histopathology 1983, 5, 525-536.
196. Paterson R., Russel M.H. Clinical trials in malignant disease. Part II — Breast cancer: value of irradiation of the ovaries. J. Faculty Radiologists, 1959, 10, 130-133.
197. Patey D.H., Dyson W.H. The prognosis of carcinoma of the breast in relation to the type of operation performed. Br.J.Cancer, 1948, 2, 7-13.
198. Petru E., Beck K., Schunemann H., Schmahl D. Bedutung des hormonorezeptorgehalts im primartumor fur die zytostatische therapie des fortgeschrittenen mammakarzinoms. Wien Med Wochenschr., 1991, 141, 7, 133-135.
199. Piccart M.J., de Valeriola D., Paridaens R. et al.- Six-Year Results of a Multimodality Treatment Strategy for Locally Advanced Breast Cancer., «Cancer»,1988, 62, 2501-2506.
200. Pinder S.E., Ellis I.O., Galea M., et al. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology, 1994, 24, 1, 41-47.
201. Ponsky J.L., Glica L., Reinolds S. Medullary carcinoma of the breast: an association with negative hormonal receptors. J. Surg. Oncology. 1984, 25, 76-78.
202. Portnoj S.M., K.P.Lactionov, R.I.Gaboonia, V.P.Godin, S.V.Shiriaev. Breast cancer (BC) course prognostication by means of intratissual beta-radiometry. XVI-th Int Cancer Congr New Delhi, 1994, PSBR5-07.
203. Portnoj S.M., Lactionov K.P. Gaboonia R.I., Godin V.P., Shiriaev S.V. Significance of the 32P incorporating level into residual tumor in breast cancer stage III patients for operability evaluation. 19-th Cong. ESMO,Lisboa, 1994. Ann Oncology, 1994, 5, Suppl. 8, P84.
204. Portnoj S.M., K.P.Lactionov, R.I.Gaboonia, V.P.Godin, S.V.Shiriaev. Prognostic significance of the level of 32P uptaking by the tumor in breast cancer (BC) patients. Sixth international congress on anti-cancer treatment Paris,1996, Abst.449.
205. Portnoj S.M., K.P. Laktionov, V.P. Letyagin, R.I. Gaboonia, V.P. Go, S.V. Shiriaev. 32P Relative Uptaking by a Tumor (32PRUT) is a Factor of Prognosis in Breast Cancer (BC) Patients. 7-th EORTC Breast Cancer Conference, Bordeaux, September 10-13 1996. PP-6 14.
206. Pritchard K.I., Trudeau M.E., Chapman J.W., et al. Prognostic variables in node-negative breast cancer: an all subset analysis. Proc Annu Meet Am Soc Clin Oncol, 1993, 12, A73.
207. Quenel N., V. Bourson, M. Durand, J.M. Dilhuydy, L. Mauriac, M. Trojani, F. Bonichon. Initial Characteristics and Outcome of Infiltrating Lobular Carcinomas (ILC): A Retrospective Study about 737 Patients. 7-th EORTC Breast Cancer Conference, Bordeaux, September 10-13 1996. PP-8 29.
208. Ranaboldo C.J., Mitchel A., Royle G.T.,et al., Axillary nodal status in women with screen-detected breast cancer. Eur J Surg Oncol, 1993, 19, 2, 130-133.
209. Ravdin P.M., Green S., Dorr T.M., McGuire W.L. et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest oncology group study. J. Clin.Oncol. 1992, 10, 8, 1284 — 1291.
210. Ravdin R.G., Iewison E.F., Slack N.H., Dao T.L., Gardner B., State D., Fisher B. Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma. Surg. Gynecol. Obstet., 1970, 31, 1055-1064.
211. Reinhardt H., Stula D., Gratzl O. — Topographic studies with 32P tumor Marker during Operations of Brain Tumors. — Eur. Surg. Res., 1985, 17, 333-340.
212. Ridolfi R.L., Rosen P.P., Post A. Medullary carcinima of the breast. A clinical pathological study with 10 year follow up. Cancer, 1977, 40, 1365-1385.
213. Roche H., Mihura J., de Lafontan B., David J.F., Naja A. Only very bad prignosis node-negative breast cancer patients deserve prospective randomized trials on adjuvant chamotherapy. Proc Annu Meet Am Soc Clin Oncol; 1991, 10, A159.
214. de la Rochefordiere A., Asselain B., Campana F., et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet, 1993, 341 (8852), 1039-1043.
215. Rosen PP, Groshen S, Kinne DW.: Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study. Journal of Clinical Oncology 9, 9, 1650-1661, 1991.
216. Rosner D., Lane W.W. Clinical determination for adjuvant therapy in axillary node-negative (ANN) breast cancer patients — ten-year follow-up. Breast Cancer Res Treat, 1991, 19, 2, 212.
217. Roy J.A., Jacob F., Leclerc G., Piccart M.J. A Retrospective Analysis of 124 Cases on the Different Clinical Outcome for Patients with ER-/PR+ Breast Tumors as Compared with ER-/PR-. European J Cancer,1996, 32a, Suppl.2, 42, ref. PP-6 -24.
218. Ryoo M.C., Kagan A.R., Wollin M. The management of infiltrating lobular cancer of the breast by either irradiation or surgery compared to a previously reported series of infiltrating ductal cancer of the breast treated by irradiation. Proceedings of the American Radium Society 78th Annual Meeting, Paris, France, April 29-May 3, 1995, p. 15.
219. Sananes S., Khairallah T., Touboul E., Salat-Baroux J., Uzan S. [Surveillance of patients treated with tamoxifen] Presse Med 1996,25, 10,499-502.
220. Schumacher M., Schmoor C., Sauerbrei W., et al. The prognostic effect of histological tumor grade in node-negative breast cancer patients. Breast Cancer Res Treat, 1993, 25, 3, 235-245.
221. Senie R,T,, Rosen P,P,, Rhodes P., et al.: Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival. Annals of Internal Medicine, 1991, 115, 5, 337-342.
222. Sigurdsson H., Baldetorp B., Borg A. et al. — Indicators of prognosis in node-negative breast cancer. N. Engl. J. Med., 1990, 322, 1045-1053.
223. Silvestrini R., Daidone M.G., Valagussa P. et al. 3H-thymidine-labelling index as a prognostic indicator in node-positive breast cancer.- J. Clin. Oncol., 1990, 8, 1321-1326.
224. Silvestrini R., Daidone M.G., Del Bino G. et al. Prognostic significance of proliferative activity and ploidy in node-negative breast cancers. Ann Oncol; 1993, 4, 3, 213-219.
225. Silvestrini R., Daidone M.G., Mastore M., et al. Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J Clin Oncol, 1993, 11, 6, 1150-1155.
226. Singh L., Wilson A.J., Baum M., et al. The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO (“Nolvadex”) trial. Br.J.Cancer, 1988, 57, 612-614.
227. Spencer R.P. — Nuclear medicine: Focus on clinical diagnosis.- N.Y., 1977, 249 p.
228. Stal O., Carstensen J., Hatschek T., Nordenskjold B. Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients. Br J Cancer, 1992, 66, 4, 706-711.
229. Stal O., Brisfors A., Carstensen J.,et al. Relationships of DNA ploidy, S-phase fraction and hormone receptor status to tumor stage in breast cancers detected by population screening. The South-East Sweden Breast Cancer Group. Int J Cancer, 1992, 51, 1, 28-33.
230. Stal O., Dufmats M., Hatschek T., et al. S-phase fraction is a prognostic factor in stage I breast carcinoma. J Clin Oncol, 1993, 11, 9, 1717-1722.
231. Steinkamp J. A., Crissman H.A. Automated analysis of deoxyribonucleic acid, protein and nuclear to cytoplasmic relationships in tumor cells and gynecologic speciments. — J.Histochem. and Cytochem., 1974, 22, 7, 616-621.
232. Stewart H.J., Forrest A.P., Everington D., McDonald C.C., Dewar J.A., Hawkins R.A., Prescott R.J., George W.D. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996,74, 2, 297-299.
233. Stonelake P.S., Baker P.G., Gillespie W.M., et al. Steroid receptors, PS2 and cathepsin D in early clinically node-negative breast cancer. Eur J Cancer, 1994, 30A, 1, 5-11.
234. Thorpe S.M., Rose C., Rasmussen B.B. et al. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node-negative primary breast cancer. — Cancer Res. ,1987, 47, 6126-6133.
235. Thorpe S.M., Christensen I.J., Rasmussen B.B., Rose C. Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. Eur J Cancer, 1993, 29A, 7, 971-977.
236. Tubiana-Hulin M., Le Doussal V., Hacene K., Rouesse J., Brunet M. Sequential identification of factors predicting distant relapse in breast cancer patients treated by conservative surgery. Cancer,1993, 72, 4, 1261-1271.
237. Tumeurs du sein. In: TNM classification des tumeurs malignes. Paris, Springer — Verlag, 1988, 99-106.
238. Del Turco MR, Palli D, Cariddi A, et al.: Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial. Journal of the American Medical Association, 1994, 271, 20, 1593-1597.
239. Turner L., Swindell R., Bell W.C., et al. Radical versus modified radical mastectomy for breast cancer. Ann Royal Coll Surg,1961, 63, 239.
240. Twelves C.J., Porter D.A., Lowry M. et al. Phosphorus-31 metabolism of post-menopausal breast cancer studied in vivo by magnetic resonance spectroscopy.Br J Cancer; 1994, 69, 6, 1151-1156.
241. Veronesi U., Banfi A., Salvadori B., et al. Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomised trial. Eur. J. Cancer, 1990, 26, 6, 668-670.
242. Veronesi U., Volterrani F., Luini A., et al. Quadrantectomy versus lumpectomy for small size breast cancer. Eur. J.Cancer, 1990, 26, 6,671-673.
243. Veronesi U., Luini A., Mariani L., et al. Effect of menstrual phase on surgical treatment of breast cancer. Lancet, 1994, 343 (8912), 1545-1547.
244. Veronesi U., Salvadori B., Luini A. Greco M., Saccozzi R., del Vecchio M., Mariani L., Zurrida S., Rilke F. Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients. Eur J Cancer 1995, 31A, 10, 1574-1579.
245. Vinnicombe S.J., MacVicar A.D., Guy R.L., et al. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology, 1996, 198, 2, 333-340.
246. Vishnyakova V.V., Kirov S., Todorov V., Peeck U., Demidov V.P., Semiglazov V.F., Bavly Ya.L., Rzhankov V., Tsiganu V.M., Madich K., Khakhanashvili G., Sikharulidze A., Pantyushenko Sh..A. The results of clinical trial within the framework of CMEA on surgical methods of mammary gland carcinoma treatment. Neoplasma, 1986, 33,5,631-639.
247. Wahl R.L., Zasadny K., Helvie M., et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol; 1993, 11, 11, 2101-2111.
248. Wasserman J., Blomgren H., Petrini B. et al.- Changes of the blood lymphocyte subpopulations and their functions following 131I treatment for nodular goitre and 32P treatment for polycythemia vera. — Int. J. Radiat. Biol., 1988, 53, 1, 159-167.
249. Wells P., Harte R.J.A., Price P. Positron emission tomography: a new investigational area for cancer research. Clin.Oncol. 1996, 8, 7-14.
250. Whelan T., Clark R., Roberts R. et al., Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial. Investigators of the Ontario Clinical Oncology Group. Int J Radiat Oncol Biol Phys, 1994, 30, 1, 11-16.
251. WHO handbook for reporting results of cancer treatment. — World Health Organisation, Geneva, 1979.
252. Witzig T.E., Ingle J.N., Schaid D.J., et al. DNA ploidy and percent S-phase as prognostic factors in node-positive breast cancer: results from patients enrolled in two prospective randomized trials. J Clin Oncol, 1993, 11, 2, 351-359.
253. Witzig T.E., Ingle J.N., Cha S.S., et al. DNA ploidy and the persentage of cells in S-phase as prognostic factors for women with lymph node negative breast cancer. Cancer, 1994, 74, 6, 1752-1761.
254. Zafrani B., C. Genestie, B. Asselain, A. Fourquet, S. Rozan, P. Validire, A. Vincent-Salomon, X. Sastre-Garau. Does Semi-Quantitative Evaluation Improve the Prognostic Value of Histological Grade in Breast Carcinoma: Comparison of Scarff-Bloom-Richardson (SBR) and Elston-Ellis (EE) Grading Systems in a Series of 825 Cases with a Follow-Up of 10 Years. 7-th EORTC Breast Cancer Conference, Bordeaux, September 10-13 1996. PP-6 5.
255. Zante J., Schumann J., Barlogie B., et al. Procedures for specific and rapid analysis of DNA distribution. — In: Pulse-Cytometry, Second International Symposium. — Belgium: European Press, Ghent, 1976, p.97-106.